Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V001-BCMA in Recurrent or Refractory Autoimmune Diseases
NCT07339540Phase 1Active, not recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of V001-BCMA in systemic lupus erythematosus (SLE), IgG4-related disease (IgG4-RD), systemic sclerosis (SSc) and 2 more, sponsored by Tongji Hospital. Primary endpoint: Incidence of adverse events at Month 24. Started Nov 2025; status: active, not recruiting.
02
Drugs
V001-BCMA
03
Conditions
systemic lupus erythematosus (SLE)IgG4-related disease (IgG4-RD)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07339540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339540.